Comparison of Abacavir Following Once-Daily And Twice-Daily Administration In HIV Infected Subjects
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The purpose of the study is to look at the levels of the drug abacavir (ABC) in blood. Also,
the study will look at the levels of carbovir triphosphate (CBV-TP), which is the active
substance produced from ABC in the bodyâ s cells which helps prevent HIV from multiplying.
CBV-TP will be measured in specific blood cells. The amount of ABC and CBV-TP will be looked
at when subjects receive ABC as a 300mg dose twice a day and compared with the levels when
they receive ABC as a 600mg dose once a day.